Oxaflozane

Oxaflozane

Clinical data
Routes of administration	Oral
ATC code	N06AX10 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-propan-2-yl-2-[3-(trifluoromethyl)phenyl]morpholine
CAS Number	26629-86-7
PubChem CID	432824
ChemSpider	382782
UNII	V4WLW77V5Q
KEGG	D07340
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H18F3NO
Molar mass	273.29 g/mol
3D model (JSmol)	Interactive image
SMILES O1CCN(C(C)C)CC1c2cc(C(F)(F)F)ccc2

WikiDoc Resources for Oxaflozane
Articles
Most recent articles on Oxaflozane Most cited articles on Oxaflozane Review articles on Oxaflozane Articles on Oxaflozane in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxaflozane Images of Oxaflozane Photos of Oxaflozane Podcasts & MP3s on Oxaflozane Videos on Oxaflozane
Evidence Based Medicine
Cochrane Collaboration on Oxaflozane Bandolier on Oxaflozane TRIP on Oxaflozane
Clinical Trials
Ongoing Trials on Oxaflozane at Clinical Trials.gov Trial results on Oxaflozane Clinical Trials on Oxaflozane at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxaflozane NICE Guidance on Oxaflozane NHS PRODIGY Guidance FDA on Oxaflozane CDC on Oxaflozane
Books
Books on Oxaflozane
News
Oxaflozane in the news Be alerted to news on Oxaflozane News trends on Oxaflozane
Commentary
Blogs on Oxaflozane
Definitions
Definitions of Oxaflozane
Patient Resources / Community
Patient resources on Oxaflozane Discussion groups on Oxaflozane Patient Handouts on Oxaflozane Directions to Hospitals Treating Oxaflozane Risk calculators and risk factors for Oxaflozane
Healthcare Provider Resources
Symptoms of Oxaflozane Causes & Risk Factors for Oxaflozane Diagnostic studies for Oxaflozane Treatment of Oxaflozane
Continuing Medical Education (CME)
CME Programs on Oxaflozane
International
Oxaflozane en Espanol Oxaflozane en Francais
Business
Oxaflozane in the Marketplace Patents on Oxaflozane
Experimental / Informatics
List of terms related to Oxaflozane

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxaflozane (Conflictan) is an antidepressant and anxiolytic drug that was introduced in France in 1982 by Solvay for the treatment of depression, but has since been abandoned. It is a prodrug to N-dealkyloxaflozane, which acts as a non-selective serotonin receptor agonist for the 5-HT_1A (pKi = 7.1), 5-HT_2A (pKi = 6.0), and 5-HT_2C (pKi = 7.5) subtypes. Oxaflozane may also have anticholinergic effects in high doses.